Canada
Mission
Keep Canadians safe from illegal online sellers of falsified medicines and to protect the integrity of Canada’s drug supply chain.
Goals
To reduce consumer purchasing of falsified, unlicensed and substandard drugs from online sellers (demand side)
To reduce the number and scope of online sellers of falsified, unlicensed and substandard drugs (supply side)
To protect the integrity of Canada’s legitimate pharmacies and drug supply chain
Click here for more information about ASOP Canada’s strategies.
Cliquez ici pour plus d’informations sur ASOP Canada Mission, Objectifs et Stratégie.
ASOP Canada Calls on Policy and Decisionmakers
Canada has a favourable international reputation, however, it is being utilized to promote the sale of falsified or substandard pharmaceutical products through illegal online pharmacies, both in Canada and abroad. The falsified market of pharmaceuticals places patients lives at risk, while also funding organized crime and terrorist networks. Canada can demonstrate leadership at the global stage by leading initiatives to better protect consumers in Canada and around the world from illegal online sellers of medicines.
Canada’s leadership on the issue of online pharmacies could benefit areas that include:
- Partner with global coalition memberships to inform consumers ( or patients/caregivers) about the risks of purchasing from illegal online pharmacies publicly on an international stage
- Strengthening enforcement actions against sellers and traffickers of falsified/substandard medicines by fostering stronger Canada-US border cooperation and enforcement
- Conduct national strategy, education and awareness programs to support a stakeholder dialogue involving all players that can directly or indirectly prevent illegal online pharmacies selling medicines to patients
In return, the members of ASOP Canada undertake to work in partnership with policymakers to provide information on the illegal activities of rogue online pharmacies, raise awareness of those acting within the legal and regulatory framework, and to collaborate in developing policies and concrete actions to tackle this serious threat to patients.